Skip to content
Screener

ARS Pharmaceuticals, Inc. SPRY Q3 2025 earnings

Reported November 10, 2025 · Before market open

Revenue$32.5MBeat by $6.9M
EPS-$0.52Miss by $0.07
Revenue estimate$25.6M
EPS estimate-$0.45

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$42.8M
EPS estimate-$0.33

Financials

Q3 2025

Income statement

See full
Revenue$32.5M+1,472%
Operating income-$53.2M-145%
Net income-$51.2M-167%
EPS (diluted)-$0.52-160%

Balance sheet

See full
Cash & equivalents$59.6M+50.2%
Total debt$97.8M+95,744%
Total equity$147.7M-26.5%
Total assets$372.8M+71.3%

Cash flow

See full
Operating cash flow-$47.0M-225%
CapEx$197.0K+40.7%
Free cash flow-$47.2M-223%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$993.2M-29.3%
Enterprise value$1.03B-24.4%
P/S7×-540×

Profitability

See full
Net margin-56.1%-27.6pp
FCF margin-60.2%-29.6pp

Returns & leverage

See full
Return on equity-45.9%-982pp
Debt / equity0.7×+0.7×
Current ratio6.7×-5.9×

FAQ

When did ARS Pharmaceuticals, Inc. report Q3 2025 earnings?
ARS Pharmaceuticals, Inc. (SPRY) reported Q3 2025 earnings on November 10, 2025 before market open.
What were ARS Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
ARS Pharmaceuticals, Inc. reported revenue of $32.5M and eps of $-0.52 for Q3 2025.
Did ARS Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $25.6M by $6.9M. EPS missed the consensus estimate of $-0.45 by $0.07.
How did ARS Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1471.6% from $2.1M a year earlier and eps declined 160.0% from $-0.20.
Where can I find ARS Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-273107) and the 10-Q periodic report (0001193125-25-273111) directly on SEC EDGAR. The filing index links above go to sec.gov.